Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Sanofi-Aventis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis 2Q08

NOTE: All amounts in Euros

2Q Revenues: EUR 6.7 billion (-4%)

2Q Earnings: EUR 1.0 billion*

YTD Revenues: EUR 13.6 billion (-4%)

YTD Earnings: EUR 2.3 billion*

Comments: Pharmaceutical revenues were up 4% for the quarter to EUR 6,032, and up 2% for HY08 to EUR 12,421. Lantus sales grew 27% in 2Q08 to EUR 576, while Lovenox sales only increased 5% to EU 637. Overall Ambien sales continued to crater, dropping 22% in 2Q08 to EUR 191. Ambien group sales are down 50% for HY08. Vaccine sales were up 17% to EUR 657, driven by 78% growth in influenza vaccines and 18% growth in adult booster vacines. For HY08, vaccine sales rose 10% to EUR 1,205. Overall sales in 2Q08 grew 12% in non-U.S./non-Europe regions; those areas were up 7% and 1%, respectively.

* Announcement did not include figures for consolidated earnings for 2Q07 or HY07, instead releasing figures that excluded certain costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters